Translation of the instructions can be
Methyluracil rectal suppositories 0.5 g
Instruction
For medical use of the medicinal product
Methyluracil
(Methyluracil)
Composition:
Active ingredient: methyluracil;
1 suppository contains 6-methyluracil 0.5 g (500 mg);
excipients: polyethylene oxide 400, polyethylene oxide 1500.
Dosage form.
Rectal suppositories.
Main physicochemical properties: white suppositories, bullet-shaped.
Pharmacotherapeutic group.
Non-steroidal anabolic agents. ATC code A14B.
Pharmacological properties.
Pharmacodynamics.
The drug has anabolic and anticatabolic effects. Accelerates regeneration, wound healing, stimulates cellular and humoral immunity, has anti-inflammatory effects. A characteristic specific property of the drug is a stimulating effect on erythropoiesis and especially leukopoiesis.
Pharmacokinetics.
When a suppository is administered rectally, the drug is well and almost completely absorbed through the mucosa and is detected in the blood after 20-30 minutes. The maximum concentration in the blood is reached after 1-2 hours. It is excreted from the body mainly by the kidneys in the form of metabolites and conjugates and partly with feces in unchanged form.
Clinical characteristics.
Indication.
Inflammatory and ulcerative diseases of the lower parts of the large intestine: ulcerative colitis, proctosigmoiditis, anal fissures.
Contraindication.
Hypersensitivity to methyluracil or to other components of the drug. The drug is contraindicated in acute and chronic (usually myeloid) forms of leukemia, lymphogranulomatosis, malignant bone marrow diseases.
Interaction with other drugs and other types of interactions.
Methyluracil enhances the effect of strophanthin, increases the effectiveness of antibiotics and sulfonamide drugs.
Application features.
Methyluracil is advisable to prescribe for mild forms of leukopenia. For moderate disease, the drug should be taken only after restoration of blood cell regeneration disorders. For severe forms of hematopoiesis, methyluracil should not be prescribed.
Use during pregnancy or breastfeeding.
Do not use the drug during pregnancy or breastfeeding.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Until the patient's individual reaction to the drug is determined, one should refrain from driving or operating other mechanisms, given that during treatment with methyluracil, such adverse reactions from the nervous system as dizziness are possible.
Method of administration and doses.
Before using the suppository, you must:
Tear off one suppository from the primary packaging along the perforation line of the blister package; pull the edges of the film, tearing it in different directions, and release the suppository from the primary packaging.
The drug is intended for rectal use.
Before insertion, moisten the suppository with water.
Adults and children over 14 years of age: 1 suppository 1-4 times a day.
The course of treatment is from 7 days to 4 months, depending on the nature of the disease.
Children.
The drug should not be used to treat children under 14 years of age.
Overdose.
Not observed.
Adverse reactions.
From the side of the central nervous system: headache, dizziness.
Skin and subcutaneous tissue disorders: allergic reactions, including hyperemia, itching, skin rashes, urticaria.
Changes at the injection site: when inserting a suppository into the rectum, a short-term burning sensation and itching are sometimes felt.
Expiration date.
3 years.
Storage conditions.
Store out of the reach of children in the original packaging at a temperature not exceeding 25 degrees Celsius.
Packaging.
5 suppositories in a blister, 1 or 2 blisters in a pack.
Vacation category.
Without a prescription.
Producer.
Private Joint-Stock Company "Lekhim-Kharkiv".
Location of production and its address of place of business.
Ukraine, 61115, Kharkiv region, Kharkiv city, Severyna Pototskoho street, building 36.
